

# Monash Investors Small Companies Trust

## Hedge Fund (ASX : MAAT)



High Conviction  
Fund



Australian Small  
Companies



Proven Track  
Record<sup>1</sup>



Buy and Sell on  
the ASX or direct

### November 2023 Fund Update

The market bounced back somewhat in November with the Fund up 8.2% after fees compared to the S&P/ASX Small Ords up 7.0% for the month.

If you recall, last month our report had us scratching our heads at the two main detractors of our performance, Impedimed and Telix (ASX: IPD, TLX). Both these stocks recovered somewhat this month with IPD up 22% and TLX up 14%. Impedimed is in the early stage of its Sozo roll out and is making good progress. This device is becoming the new standard of care for monitoring post-operative cancer patients for lymphedema.

Telix has a bigger addressable market than Impedimed, and is much more advanced in its product roll out. It provides radiopharmaceuticals for cancer patients. It is a cash flow positive business with sales already over \$500m pa for its prostate cancer imaging product and growing strongly. In the next 6-9 months it will launch its renal cancer imaging product. It has several other clinical programs underway to provide imaging for other cancers and also to assess whether its drugs may be used therapeutically using higher doses of radiation. The results so far are promising.

Despite the outsized level of volatility in these two stocks, their outlook over the next few years is strong with our valuations for both stocks well above 60% upside from here.

Our retailers were also good contributors to the return this month with Temple & Webster (ASX: TPW) up 45% and Lovisa (ASX: LOV) up 11%. Both stocks

### Return Summary<sup>1</sup> (after all fees)

1 Month	3 Months
+8.2%	-7.0%
1 Year	Since Inception
-6.5%	-2.7% <sub>pa</sub>



Our Investment team: Sebastian Correia, Simon Shields and Shane Fitzgerald

This fund is appropriate for investors with "High" and "Very High" risk and return profiles. A suitable investor for this fund is prepared to accept high risk in the pursuit of capital growth with a medium to long investment timeframe. Investors should refer to the [TMD](#) for further information.

<sup>1</sup> Inception date is 28 May 2021. Past performance is not indicative of future performance.

# Monash Investors Small Companies Trust

## Hedge Fund (ASX : MAAT)

had Annual General Meetings this month where they provided post year end updates. Both stocks have strong structural growth.

TPW is Australia's leading online furniture retailer, and its market share of the total furniture market has been growing strongly. In the four months since June, sales were up 23% versus pcp compared to market expectations of 15%. This compared to Harvey Norman (ASX: HVN) with a sales decline of -12% and Nick Scali (ASX: NCK) with sales orders down -5% for 1Q FY 2024. The stock price of TPW rose strongly on the back of this result.

By contrast, Lovisa is undertaking a "bricks and mortar" global store rollout. Despite a challenging jewelry retailing market in the four months since June with its same store sales declining by -6%, overall

sales have grown 17% versus pcp. Given the weak same store sales the stock price initially fell, but given its overall sales growth, the continued strength of its gross profit margin, and critically the announcement of the first store opening in mainland China, the price had turned around by the end of the day.

The Fund's major exposures continue to be to Healthcare, Consumer Discretionary, IT, Energy (via Uranium), and Mining Services.

Monash Investors aims to identify businesses which are likely to undergo step-changes (either positive or negative) in their business prospects which will lead to material share price movements. We draw upon our experience in order to exploit recurring business situations and patterns of behaviour, to identify and invest in a portfolio of compelling opportunities.

### Return Summary Since Inception (after fees)<sup>2</sup>

	MAAT	Small Ords
CYTD	-2.52%	0.56%
FYTD	-4.08%	-0.76%
1 month	8.17%	7.04%
3 Month	-6.99%	-2.88%
6 Month	-1.24%	-0.73%
1 Year	-6.54%	-3.19%
2 Years pa	-8.38%	-8.77%
Since Inception pa	-2.68%	-4.45%

### Return Summary Since Inception (after fees)<sup>2</sup>

	MAIF	Small Ords
CYTD	-1.70%	0.56%
FYTD	-3.62%	-0.76%
1 month	7.63%	7.04%
3 Month	-6.58%	-2.88%
6 Month	-0.84%	-0.73%
1 Year	-5.89%	-3.19%
2 Years pa	-7.73%	-8.77%
3 Years pa	-0.12%	-0.48%
4 Years pa	6.21%	1.10%
5 Years pa	9.92%	4.03%
7 Years pa	7.15%	5.39%
Since Inception pa	8.97%	5.32%

<sup>2</sup>Due to lack of MAAT history, data from Monash Small Companies Fund (MAIF) (inception date 2 July 2012) has been used. Glossary of terms can be found on the Fund's website at [www.monashinvestors.com/glossary/](http://www.monashinvestors.com/glossary/)

# Monash Investors Small Companies Trust

## Hedge Fund (ASX : MAAT)

### **For MAAT Unit Registry enquiries, please contact**

Apex Fund Services Pty Limited  
P: 1300 133 451 (in Australia)  
+61 2 8259 8888 (international)  
E: [registry@apexgroup.com](mailto:registry@apexgroup.com)

### **For all business development enquiries, please contact**

Cameron Harris  
P: +61 400 248 435  
[cameron@gsmcapital.com.au](mailto:cameron@gsmcapital.com.au)

**For more information about MAAT and the strategy, please refer to the Monash Investors website at [www.monashinvestors.com](http://www.monashinvestors.com). You can also [follow us on Livewire here](#) or [subscribe to our updates here](#)**

This document is prepared by Monash Investors Pty Limited ABN 67 153 180 333, AFSL 417 201 ("Monash Investors") as authorised representatives of Sanlam Private Wealth Pty Ltd ABN 18 136 960 775, AFSL 337 927 ("Sanlam") for the provision of general financial product advice in relation to the Monash Investors Small Companies Trust (Hedge Fund) ARSN 642 280 331 ("Fund") and authorised for release by The Trust Company (RE Services) Limited ABN 45 003 278 831, AFSL 235 150 ("Perpetual") as the responsible entity of, and issuer of units in the Fund. Monash Investors is the investment manager of the Fund. A Product Disclosure Statement ("PDS") dated 17 July 2023 together with a Target Market Determination ("TMD"), both issued by Perpetual, is available for the Fund at [www.monashinvestors.com](http://www.monashinvestors.com). You should obtain and consider the PDS and TMD for the Fund before deciding whether to acquire, or continue to hold, an interest in the Fund. The information provided is general information only and is not intended to provide you with financial advice, it does not consider your investment objectives, financial situation or particular needs. You should consider your own investment objectives, financial situation and particular needs before acting upon any information provided and consider seeking advice from a financial advisor if necessary. To the extent permitted by law, no liability is accepted for any loss or damage as a result of any reliance on this information. No company in Perpetual Group (Perpetual Limited ABN 86 000 431 827 and its subsidiaries) guarantees the performance of any fund or the return of an investor's capital.

You should not base an investment decision simply on past performance. Past performance is not a reliable indicator of future performance. Returns are not guaranteed and so the value of an investment may rise or fall. Total returns shown have been calculated using NAV prices after taking into account all ongoing fees and assuming reinvestment of distribution. No allowance has been made for taxation. Comparisons are provided for information purposes only and are not a direct comparison against benchmarks or indices that have the same characteristics as the Fund. Reference to Target Distributions, is a target return only. There is no guarantee the Fund will meet its investment objective. The payment of a quarterly distribution is a goal of the Fund only and neither Monash Investors or Perpetual provide any representations or warranty (whether express or implied) in relation to the payment of any quarterly cash income. The Fund reserves the discretion to amend its distribution policy.

The rating contained in this document is issued by SQM Research Pty Ltd ABN 93 122 592 036 AFSL 421913. SQM Research is an investment research firm that undertakes research on investment products exclusively for its wholesale clients, utilising a proprietary review and star rating system. The SQM Research star rating system is of a general nature and does not take into account the particular circumstances or needs of any specific person. The rating may be subject to change at any time. Only licensed financial advisers may use the SQM Research star rating system in determining whether an investment is appropriate to a person's particular circumstances or needs. You should read the product disclosure statement and consult a licensed financial adviser before making an investment decision in relation to this investment product. SQM Research receives a fee from the Fund Manager for the research and rating of the managed investment scheme.